All the Different Types of THC and Their Effects

Delta-9-THC is the compound most people mean when they say “THC,” but it is far from the only version. The cannabis plant produces several naturally occurring THC variants, and the modern hemp-derived market has introduced even more through chemical conversion. Each type interacts differently with the body’s cannabinoid receptors, producing effects that range from intensely psychoactive to essentially inert. Understanding these differences matters because many of these compounds are now sold in shops and online with little regulation and widely varying quality.

Delta-9-THC, the One Everyone Knows

Delta-9-tetrahydrocannabinol is the primary psychoactive compound in cannabis. It works as a partial agonist at the body’s CB1 and CB2 cannabinoid receptors, and the strength of its effects depends partly on how many of those receptors are available and how efficiently they signal in a given person’s body.¹ This is why the same dose can hit two people quite differently.

When you eat delta-9-THC rather than inhaling it, the liver converts a large share of it into 11-hydroxy-THC, an active metabolite that crosses into the brain more easily and tends to produce stronger, longer-lasting effects. Oral dosing also generates high levels of a further breakdown product, THC-COOH, which is what most drug tests actually detect.² That metabolic step through the liver is why edibles can feel so much more potent than smoking, even at equivalent THC doses. Both THC and CBD show therapeutic promise, but chronic THC use has been linked to increased risk of mental health problems, and high-dose CBD carries its own side effects.³

Delta-8-THC

Delta-8-THC became the breakout product of the post-2018 hemp market. Structurally, it is almost identical to delta-9, with a double bond shifted by just one position on the carbon chain. That tiny shift reduces its ability to bind to the CB1 receptor, which accounts for its weaker psychoactive punch.⁴ Users frequently describe delta-8 as producing a milder, less anxious high than delta-9, though controlled clinical data comparing the subjective experiences head-to-head remain limited.

Almost all delta-8 products on shelves are not extracted from cannabis. Instead, they are chemically converted from CBD, which can be derived from legal hemp. The conversion process is surprisingly straightforward, essentially CBD plus an acid catalyst plus time.⁵ That simplicity is part of what fueled the delta-8 boom, but it also means the conversion can produce unwanted byproducts if it is not done carefully. One commonly found contaminant in delta-8 products is olivetol, a chemical precursor used in THC synthesis. Swiss customs officials seized hundreds of kilograms of olivetol and related precursors in 2019, suggesting large-scale synthetic production was already underway well before most consumers had ever heard of delta-8.⁵

Delta-10-THC

Delta-10-THC is often marketed as the “energizing” or “sativa-like” THC isomer, but the pharmacology tells a more complicated story. In receptor binding tests, both the trans and cis forms of delta-10 showed significantly lower affinity for the CB1 receptor than delta-9. The trans isomer bound CB1 with about 14 times less affinity than delta-9, while the cis isomer was roughly 140 times weaker. More importantly, in functional assays designed to measure whether a compound actually activates the receptor, neither delta-10 isomer triggered any agonist response at all, even at high concentrations.⁶ That suggests delta-10 may lack meaningful THC-like psychoactivity on its own, and some researchers have proposed it could even act as an antagonist, blocking the receptor rather than stimulating it.⁷

If delta-10 truly has negligible agonist activity at CB1, then the “high” people report from delta-10 products could be partly explained by contamination with small amounts of delta-8 or delta-9 produced during manufacture. Standard HPLC testing used by many hemp labs has difficulty separating delta-8, delta-9, and several other THC isomers, which makes accurate labeling a persistent challenge.⁸

THCV, the Appetite Antagonist

Tetrahydrocannabivarin, or THCV, is a naturally occurring cannabinoid found in certain cannabis strains, particularly some African landrace varieties. What makes it unusual is that it does the opposite of what people associate with THC at the CB1 receptor: instead of activating it, THCV blocks it. That antagonist action at CB1, combined with partial agonist activity at CB2, gives THCV a pharmacological profile tied to appetite suppression, improved glucose regulation, and increased energy expenditure.⁹

Because of those properties, THCV has attracted interest as a possible treatment for metabolic disorders like type 2 diabetes and obesity. At low doses, it does not appear to produce a high. At higher doses, some psychoactivity can emerge, but the character of the experience is often described as clear-headed and short-lived. THCV is not abundant in most commercial cannabis strains, so products containing concentrated THCV tend to be specialty items and often carry a premium price.

THCP, the Extremely Potent Newcomer

Tetrahydrocannabiphorol, or THCP, was first isolated from cannabis in 2019 by Italian researchers, and it immediately attracted attention for one reason: its binding affinity at the CB1 receptor was about 33 times stronger than delta-9-THC’s. THCP bound CB1 with a Ki of 1.2 nanomolar, compared to 40 nanomolar for delta-9-THC.¹⁰ That stronger binding comes from THCP’s longer side chain: seven carbon atoms instead of the five on delta-9-THC. In mouse studies, THCP produced cannabinoid-like effects at lower doses than delta-9.

The practical takeaway is that THCP is far more potent by weight. Products containing it require much smaller doses to produce strong effects, and overconsumption is easy if you are not paying attention to labels. THCP occurs naturally in cannabis but in very small concentrations. Most THCP on the retail market is synthesized, often from CBD through a multi-step chemical process. The same binding-affinity advantage that makes it interesting pharmacologically also makes it riskier for casual users who are accustomed to delta-9 dosing.

THCA, the Raw Precursor

Tetrahydrocannabinolic acid, or THCA, is what the cannabis plant actually produces. It is the acidic precursor to delta-9-THC and is not psychoactive in its natural form. THCA converts into delta-9-THC through decarboxylation, which is a fancy way of saying it loses a carboxyl group when exposed to heat. This is why raw cannabis does not get you high until you smoke it, vape it, or bake it.

The conversion is temperature-dependent. At temperatures below about 100°C, the reaction is slow and incomplete within an hour. At 110°C, THCA fully converts in roughly 30 minutes. Push the temperature to 145°C and you get complete conversion in about 6 minutes.¹¹ This is why low-temperature cooking can leave some THCA unconverted, and why lighting a joint or taking a dab at high heat gives a full conversion almost instantly.

THCA has become a legal gray area in the United States. Because THCA itself is not delta-9-THC, some retailers sell high-THCA hemp flower that tests below the federal 0.3% delta-9 threshold on paper but converts into full-strength THC the moment you apply heat. Whether regulators will close this loophole remains an evolving question.

HHC, the Hydrogenated Version

Hexahydrocannabinol, or HHC, is what you get when you add hydrogen atoms to the THC molecule, a process similar to turning vegetable oil into margarine. The result is a more chemically stable compound. HHC exists as two epimers, labeled 9R and 9S, and they behave very differently. In mice, the 9R form significantly reduced spontaneous activity and produced measurable pain relief, increasing the time animals could tolerate a hot surface before reacting. The 9S form, by contrast, did neither.¹²

This matters because commercially sold HHC products contain a mixture of both forms, and the ratio varies depending on the manufacturing process. A product with a higher share of 9R-HHC will feel more potent than one loaded with 9S-HHC, but consumers have no way of knowing the ratio from a typical product label. User reports generally place HHC somewhere between delta-8 and delta-9 in terms of psychoactive strength, though the variability between products makes generalizing difficult.

THC-O-Acetate and Safety Red Flags

THC-O-acetate, often styled as THC-O or THCO, is an acetate ester of THC. It gained popularity for claims of being two to three times stronger than delta-9, though controlled clinical data supporting that number is thin. The more pressing concern is safety: heating THC-O can produce ketene, a toxic gas that damages lung tissue.¹³ This risk is specific to vaping and dabbing, where the compound is exposed to high temperatures directly. The concern is serious enough that the DEA issued guidance classifying THC-O as a controlled substance because it does not occur naturally in the plant, and several states have moved to ban it explicitly.

THC-O is worth singling out because it illustrates a broader pattern in the unregulated cannabinoid market. Compounds get popular based on user reports before any meaningful safety testing occurs. By the time researchers identify a hazard like ketene formation, millions of units have already been sold and consumed.

The CBD-to-THC Pipeline and Why Purity Matters

Most of the newer THC variants sold today share a common origin story. The 2018 Farm Bill legalized hemp and, with it, CBD derived from hemp. Manufacturers then discovered they could chemically convert inexpensive CBD into delta-8, delta-10, HHC, THCP, and other cannabinoids.¹⁴ The legal argument was that if the starting material was legal hemp-derived CBD, the end product should also be legal. Regulators and courts have not universally agreed.

The conversion processes, while chemically straightforward, can leave behind unwanted byproducts including residual acids, heavy metals from catalysts, and trace amounts of unintended cannabinoid isomers. Without mandatory third-party testing and standardized manufacturing practices, the quality of these products varies enormously from brand to brand. A certificate of analysis, or COA, is the minimum a consumer should look for, and even then, the testing lab’s ability to distinguish between closely related THC isomers is limited by current analytical technology.⁸

Drug Testing and Cross-Reactivity

If you use any of these THC variants and are subject to drug testing, the practical outcome is the same: you will likely test positive. Standard urine immunoassay kits cross-react with delta-8-THC, delta-10-THC, HHC metabolites, and their breakdown products.¹⁵ The tests are designed to detect THC-COOH and structurally similar metabolites, and the newer cannabinoids produce metabolites close enough to trip the assay.

HHC specifically has driven a noticeable increase in false-positive THC screening results. In one analysis, the rate of false positives for THC in oral fluid and urine rose from less than 2% to over 10% as HHC use became more common, and spiking experiments confirmed that HHC and several of its analogs cross-react with the antibodies used in commercial screening kits.¹⁶ The idea that delta-8 or HHC “won’t show up on a drug test” is one of the most persistent and consequential myths in the alternative cannabinoid space.

How Tolerance Develops Across THC Types

Frequent use of any THC variant that activates the CB1 receptor leads to tolerance. The underlying mechanism is receptor downregulation: the brain responds to chronic stimulation by reducing the number of available CB1 receptors on cell surfaces. Brain imaging of daily cannabis smokers has confirmed this, showing decreased CB1 receptor availability that reverses after a period of abstinence.¹⁷ The downregulation is region-specific, meaning different brain areas lose receptor density at different rates, which may help explain why some effects fade faster than others with regular use.

Animal studies confirm that this receptor downregulation is dose-dependent and occurs in a region-specific pattern across multiple brain areas over days to weeks of exposure.¹⁸ In practical terms, if you develop tolerance to delta-9-THC, you will likely have cross-tolerance to delta-8, THCP, and other CB1 agonists as well. THCV, with its CB1 antagonist activity, would be the exception.

Cannabis Hyperemesis and Dose-Dependent Effects

One consequence of heavy, long-term THC use that catches people off guard is cannabis hyperemesis syndrome, or CHS. The condition involves cycles of severe nausea and vomiting, often relieved temporarily by hot showers or baths. The mechanism involves the endocannabinoid system’s dual role in the gut: at lower doses, cannabinoids tend to be anti-nausea; at higher doses and with chronic exposure, they can flip to pro-emetic. CB1 receptors in the intestinal nerve network have an inhibitory effect on gut motility, and the disruption of temperature regulation through endocannabinoid pathways may explain the compulsive hot bathing that many CHS patients report.¹⁹

CHS has been documented primarily with delta-9-THC, but the mechanism suggests that any potent CB1 agonist used heavily over time could trigger it. Whether THCP’s extreme receptor affinity makes it more or less likely to cause CHS at a given dose is a question nobody has studied yet. Consumers switching from delta-9 to alternative cannabinoids specifically to avoid nausea should not assume the risk disappears.

The Entourage Effect and Why Isolates Differ From Whole Plant

Cannabis produces over a hundred cannabinoids alongside dozens of terpenes, and there is a longstanding hypothesis that these compounds work differently together than they do in isolation. The “entourage effect” is the term for this proposed synergy, particularly the idea that terpenes can modify or enhance the effects of cannabinoids.²⁰

The entourage effect is relevant to the THC variants discussion because most alternative cannabinoid products are isolates or distillates produced from converted CBD. They lack the terpene and minor cannabinoid profile you would find in whole-plant cannabis. Some manufacturers add terpenes back in, but whether re-added terpenes replicate the original plant’s effect profile is debatable. The science here is genuinely incomplete. Some researchers consider the entourage effect well-supported by preclinical evidence. Others argue it has been oversold and that human clinical trials have not clearly demonstrated it. For the consumer, the practical difference is that a delta-8 distillate vape and a delta-8 product blended with cannabis-derived terpenes may feel different, even at the same THC concentration, and neither will feel exactly like smoking whole-plant cannabis.

How Labs Tell These Compounds Apart

Analytical chemistry has been scrambling to keep up with the explosion of THC variants. The standard workhorse method for cannabinoid testing, high-performance liquid chromatography, struggles to separate several THC isomers from each other. Delta-8 and delta-9 tend to blend together on an HPLC readout, as do several rarer isomers. Gas chromatography provides better separation for these coeluting compounds and has become the industry’s preferred tool for distinguishing closely related THC variants.⁸

This is not just an academic problem. If a lab cannot reliably tell delta-8 from delta-9 in a product, compliance testing becomes unreliable. A hemp product could test as legal when it actually contains enough delta-9-THC to violate federal thresholds. Improved HPLC methods are being developed specifically to address these separation issues, but adoption across the testing industry is uneven. For consumers, this means that even a product with a lab report attached may not have been tested with methods capable of accurately distinguishing between the THC isomers it contains.